

### Graduate Student Trainees Supervised by C. Daniel Mullins

Past / Current Trainee	Training Period	Prior Academic Degree Institution(s)	Prior Academic Degree(s)	Title of Dissertation	Current Position of Past Trainees / Source of Support of Current Trainees
<i>Joseph Vandigo</i>	2010 - current	Univ of Louisiana Monroe; Southeastern Louisiana Univ	MBA  BS	Impact of Medicare Contracting Reform on Colon Cancer Treatment and Outcomes	<i>U.S. Dept. of Education, NHLBI, PCORI, AHRQ</i>
<i>Abdulla Aly</i>	2009 - current	Misr Internat. University (Egypt)	BSP Pharm	The impact of heterogeneity of treatment effect on survival, cost effectiveness, and coverage of androgen deprivation therapy in metastatic prostate cancer	<i>Amgen (PI = Arif Hussain, MD)</i>
<i>Emily Reese</i>	2008 - current	Univ of South Carolina; Charleston Southern Univ	MPH  BS	Value of Information: the contribution of the PSA screening test to Prostate Cancer diagnosis	<i>PhRMA Foundation Dissertation Grant</i>
Mark Maneval	2007 - 2012	University of Rhode Island	BSP Pharm	Estimating direct medical costs and their variation across heterogeneous Multiple Sclerosis (MS) patients in the Veterans Health Administration	US Military
Nneka Onwudiwe	2005 - 2012	University of Maryland Baltimore	PharmD	Modern Methods of Delivering Adjuvant Radiation Treatment and the Risk of Cardiac Injury in Breast Cancer	Pharmacoeconomics/ PRO Regulatory Review Officer, US FDA
Satish C. Valluri	2005- 2009	Ohio State University	MS	Impact of Food and Drug Administration pediatric Antidepressant use Warnings on Treatment of Depression, Physician Specialty Practice Patterns, and Pharmaceutical Stock Prices	Global Project Leader, Bayer Healthcare Pharmaceuticals
Dongyi Du	2004- 2009	Changchun Institute of Biological Products	MS	Short-term Impact of Direct-to-Consumer Advertising on the Selection of Antihypertensive Medication	Commissioner's Fellow, FDA
Jing (Julia) Ju	2005 - 2008	University of Maryland Baltimore	PharmD	Metabolic Syndrome: A Cluster of Risk Factors for Hospitalizations and Medical Costs	Epidemiologist, Division of Epidemiology, Office of Surveillance and Epidemiology, CDER, FDA

<b>Past / Current Trainee</b>	<b>Training Period</b>	<b>Prior Academic Degree Institution(s)</b>	<b>Prior Academic Degree(s)</b>	<b>Title of Dissertation</b>	<b>Current Position of Past Trainees / Source of Support of Current Trainees</b>
Nour Obeidat	2001 – 2008	Jordan University of Science and Tech	BS	Use and Outcomes of Novel Chemotherapeutic Agents in Colorectal Cancer	Head of the Center for Health Economics and Outcomes Research at King Hussein Institute for Biotechnology and Cancer
Prasun Subedi	2000 – 2008	Dickinson College	BS	Relationship between surrogate endpoints and short-term resource utilization	Director, Worldwide Policy, Pfizer
Danielle Chauncey Lavallee	2003 - 2007	University of Kansas	PharmD	Assessing the impact of incorporating patient knowledge and beliefs into Anticoagulation Therapy Management Services	Survey Center Manager Surgical Outcomes Research Center Univ of Washington; Research Director / Patient and Consumer Alliance Coordinator, Center for Medical Technology Policy
Betina Blak	1999-2006	The Royal Danish School of Pharmacy	MS	Utilization Patterns and Drug Budget Impact of Angiotensin II Receptor Blockers (ARBs)	Real World Evidence Analyst, AstraZeneca UK Ltd
Junling Wang	1999 – 2005	Shandong Medical University	MS	Racial/Ethnic Disparities in Access to Prescription Drugs During Early Years of Drug Products' Life Cycles	Associate Professor, University of Tennessee
Simu Thomas	1997 – 2002	University of Toledo	MS	Impact of Technology Advances on Cost Effectiveness of Drugs	HE&OR Head - Neuroscience and Ophthalmics, Novartis Pharmaceuticals Corporation
Xing-Yue Huang	1996 – 2001	University of North Carolina	MS	Modeling Costs and Opportunities Infections for Medicaid HIV/AIDS Patients: Effect of Patient Non-Adherence	Director, Health Outcomes, Forest Laboratories, Inc
Sanjay Merchant	1996 – 2001	University of Toledo	MS	An Economic Model for Patients Hospitalized with Community-Acquired Pneumonia	Director, Worldwide Market Access, Global Strategic Marketing & Market Access Janssen Global Services, LLC
Shelby Ogilvie Reed	1993 – 1998	University of Maryland Baltimore	PharmD	Costs, Outcomes and Estimation of the Cost-Effectiveness of Abciximab in the Prevention of Ischemic Events Over Six Months of Follow-up	Associate Research Professor of Medicine, Duke University